|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Fecal immunochemical test accuracy in average-risk colorectal cancer screening显示文摘AIM:To assess the fecal immunochemical test(FIT)accuracy for colorectal cancer(CRC)and advanced neoplasia(AN)detection in CRC screening.METHODS:We performed a multicentric,prospective,double blind study of diagnostic tests on asymptomatic average-risk individuals submitted to screening colonoscopy.Two stool samples were collected and the fecal hemoglobin concentration was determined in the first sample(FIT1)and the highest level of both samples(FITmax)using the OC-sensor.Areas under the curve(AUC)for CRC and AN were calculated.The best FIT1and FITmax cut-off values for CRC were determined.At this threshold,number needed to scope(NNS)to detect a CRC and an AN and the cost per lesion detected were calculated.RESULTS:About 779 individuals were included.An AN was found in 97(12.5%)individuals:a CRC in 5(0.6%)and an advanced adenoma(≥10 mm,villous histology or high grade dysplasia)in 92(11.9%)subjects.For CRC diagnosis,FIT1 AUC was 0.96(95%CI:0.95-0.98)and FITmax AUC was 0.95(95%CI:0.93-0.97).For AN,FIT1 and FITmax AUC were similar(0.72,95%CI:0.66-0.78 vs 0.73,95%CI:0.68-0.79,respectively,P=0.34).Depending on the number of determinations and the positivity threshold cut-off used sensitivity for AN detection ranged between 28%and 42%and specificity between 91%and 97%.At the best cut-off point for CRC detection(115 ng/mL),the NNS to detect a CRC were 10.2 and 15.8;and the cost per CRC was 1814€and 2985€on FIT1 and FITmax strategies respectively.At this threshold the sensitivity,NNS and cost per AN detected were 30%,1.76,and 306€,in FIT1 strategy,and 36%,2.26€and 426€,in FITmax strategy,respectively.CONCLUSION:Performing two tests does not improve diagnostic accuracy,but increases cost and NNS to detect a lesion. | Vicent Hernandez Joaquin Cubiella M Carmen Gonzalez-Mao Felipe Iglesias Concepción Rivera M Begoa Iglesias Lucía Cid Ines Castro Luisa de Castro Pablo Vega Jose Antonio Hermo Ramiro Macenlle Alfonso Martínez-Turnes David Martínez-Ares Pamela Estevez Estela Cid M Carmen Vidal Angeles López-Martínez Elisabeth Hijona Marta Herreros-Villanueva Luis Bujanda Jose Ignacio Rodriguez-Prada the COLONPREV study investigators | 2014 | World Journal of Gastroenterology2014，20，4： | 4 |
| 2 | 青少年和年轻成人先天性心脏病的心理社会远期转归显示文摘目的先天性心脏病(CHD)是一种在全球范围内高发的慢性疾病,通常在出生时或出生前确诊。由于诊断以及早期药物和手术治疗的条件较好,患者的生存率达到90%,并且生存时间不断延长,面临着生活中的各种挑战。该研究探讨了不同人口统计学、临床和心理社会变量对CHD青少年和年轻成人患者的生活质量(QOL)感知、心理社会适应和精神障碍患病率的影响,评估CHD青少年和年轻成人患者的生活质量、心理社会适应和精神障碍发病率,确定哪些变量(人口统计学、临床和心理社会变量)对缓解压力、促进恢复起到积极作用,哪些变量起到不良作用。方法该研究入组了150名CHD患者(男87例,女63例),年龄12~26岁(平均年龄:17.45±3.373岁)。对参与者进行了关于社会支持、家庭教育方式、自我形象、人口统计信息和生理限制等方面的访谈。他们对标准化精神病学访谈(SADS-L)中的问题进行了回答,并填写了自我报告问卷,以进行生活质量(WHOQOL-BREF)和心理社会适应(YSR/ASR)的评估。结果所有参与者精神障碍的终身患病率为18.7%(女性25.4%,男性13.8%)。57.1%的参与者有过留级(平均1.53±0.804年)。与整体葡萄牙人相比,CHD患者的生活质量感知在社会关系、环境、身体和总体方面较好。而女性、学习成绩差、较少的社会支持、复杂性CHD、紫绀型CHD、中重度残留病灶、接受过手术和有生理限制患者生活质量感知较差。除了紫绀,所有这些变量也会引起较差的心理社会适应。结论女性CHD患者及学习成绩差且获得社会支持少的CHD患者的心理社会适应和生活质量较差。 | Maria Emlha Gulmaraes Arelas Catarina I. Pinto Patricia F. Vieira Flavio Teixeira Rosalia. Coelho Isabela Freitas Samantha Matos Marta Castro Sofia Sarmento Victor Viana Jorge Quintas Jose C. Areias | 2013 | 中国当代儿科杂志2013，15，10： | 3 |
| 3 | Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression显示文摘 | María J. Bueno Ignacio Pérez de Castro Marta Gómez de Cedrón Javier Santos George A. Calin Juan C. Cigudosa Carlo M. Croce José Fernández-Piqueras Marcos Malumbres | 2008 | Cancer Cell2008，，： | 2 |
| 4 | Does music perception have an impact on quality of life following cochlear implantation?显示文摘 | Luis Lassaletta Alejandro Castro Marta Bastarrica Rosa Pérez-Mora Rosario Madero Josefa De Sarriá Javier Gavilán | 2007 | Acta Oto-Laryngologica2007，，7： | 1 |
| 5 | Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression显示文摘 | Mara J Bueno Ignacio Pérez de Castro Marta G ómez de Cedrón | 2008 | Cancer Ce112008，13，6： | 1 |
| 6 | IL-10 modulates serotonin transporter activity and molecular expression in intestinal epithelial cells显示文摘 | Eva Latorre Carmen Mendoza Nyurky Matheus Marta Castro Laura Grasa José E. Mesonero Ana I. Alcalde | 2013 | Cytokine2013，，： | 1 |
| 7 | Innovation in services industries: current and future trends显示文摘 | Castro L M Angeles Montoro-Sanchez Marta Ortiz-De-Urbina- Criado | 2011 | The Service Industries Journal2011，31，1： | 1 |
| 8 | Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease显示文摘 | Lidia Anguiano Marta Riera Julio Pascual José Manuel Valdivielso Clara Barrios Angels Betriu Sergi Mojal Elvira Fernández María José Soler Eva Castro Virtudes María Teresa Molí Meritxell Soria Aladrén Regidor Ma José Almirall Jaume Ponz Esther Arteaga Col | 2015 | Nephrology Dialysis Transplantation2015，，7： | 1 |
| 9 | Impact of preformed donor-specific antibodies against HLA class Ⅰ on kidney graft outcomes:Comparative analysis of exclusively anti-Cw vs anti-A and/or-B antibodies显示文摘AIM To analyze the clinical impact of preformed antiH LA-Cw vs antiH LA-A and/or-B donor-specific antibodies(DSA) in kidney transplantation.METHODS Retrospective study, comparing 12 patients transplanted with DSA exclusively antiH LA-Cw with 23 patients with preformed DSA antiH LA-A and/or B.RESULTS One year after transplantation there were no differencesin terms of acute rejection between the two groups(3 and 6 cases, respectively in the DSA-Cw and the DSA-A-B groups; P = 1). At one year, eG FR was not significantly different between groups(median 59 mL /min in DSA-Cw group, compared to median 51 mL /min in DSA-A-B group, P = 0.192). Moreover, kidney graft survival was similar between groups at 5-years(100% in DSA-Cw group vs 91% in DSA-A-B group, P = 0.528). The sole independent predictor of antibody mediated rejection(AMR) incidence was DSA strength(HR = 1.07 per 1000 increase in MFI, P = 0.034). AMR was associated with shortened graft survival at 5-years, with 75% and 100% grafts surviving in patients with or without AMR, respectively(Log-rank P = 0.005).CONCLUSION Our data indicate that DSA-Cw are associated with an identical risk of AMR and impact on graft function in comparison with 'classical' class I DSA. | Sofia Santos Jorge Malheiro Sandra Tafulo Leonídio Dias Rute Carmo Susana Sampaio Marta Costa Andreia Campos Sofia Pedroso Manuela Almeida La Salete Martins Castro Henriques António Cabrita | 2016 | World Journal of Transplantation2016，6，4： | 1 |
| 10 | Vaccination with a mutated variant of human Vascular Endothelial Growth Factor (VEGF) blocks VEGF-induced retinal neovascularization in a rabbit experimental model显示文摘 | Yanelys Morera Rafael González Humberto Lamdan Lincidio Pérez Yorlandis González Judith Agüero Jorge Castro Juan C. Romero Ana Yansy Etchegoyen Marta Ayala Jorge V. Gavilondo | 2014 | Experimental Eye Research2014，，： | 1 |
| 11 | Simultaneous determination of vitamins A and E in rat tissues by high-performanceliquid chromatography显示文摘 | Coral Barbas Mario Castro Bartolome Bonnet Marta Viana EmilioHerrera | 1997 | Journal of Chromatography A1997，778，： | 1 |
| 12 | Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials显示文摘 | Simona Silvetti Teresa Greco Ambra Licia Di Prima Marta Mucchetti Castro Maria de Lurdes Laura Pasin Mara Scandroglio Giovanni Landoni Alberto Zangrillo | 2014 | Clinical Research in Cardiology2014，，7： | 1 |
| 13 | Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression显示文摘 | María J. Bueno Ignacio Pérez de Castro Marta Gómez de Cedrón Javier Santos George A. Calin Juan C. Cigudosa Carlo M. Croce José Fernández-Piqueras Marcos Malumbres | 2008 | Cancer Cell2008，，6： | 1 |
| 14 | Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn's disease显示文摘BACKGROUND Identifying predictors of therapeutic response is the cornerstone of personalized medicine.AIM To identify predictors of long-term mucosal healing(MH) in patients with Crohn's disease(CD) treated with tumor necrosis factor α(TNF-α) inhibitors.METHODS Prospective single center study. Consecutive patients with clinically active CD requiring treatment with a TNF-α inhibitor were included. A baseline segmental CD Endoscopic Index of Severity(CDEIS) ≥ 10 in at least one segment or the presence of ulcerations were required for inclusion. Clinical, biological and endoscopic data were obtained at baseline, weeks 14 and 46. Endoscopic response(ER) was defined as a decrease ≥ 50% from baseline CDEIS and MH as partial CDEIS ≤ 5 in all segments.RESULTS Of 62 patients were included. At baseline, median CD Activity Index and CDEIS were 201 and 6.7, respectively with a significant reduction after one year of treatment(53 and 3.0 respectively, P < 0.001). At week 14, 56% of patients achieved ER and 34% MH. At week 46, the corresponding percentages were 52%and 44%. Baseline disease characteristics or biomarkers did not predict MH. A decrease from baseline CDEIS at week 14 of at least 80% was the best predictor of MH at week 46(59% sensitivity and 91% specificity; area under the curve =0.778).CONCLUSION Clinical and biomarker data are not useful predictors of response to TNF-αinhibitors in CD, whereas ER to induction therapy, defined as 80% reduction in global CDEIS, is a robust predictor of long-term MH. Achievement of this endoscopic endpoint may be considered as a therapeutic target for anti-TNF-αtherapy. | Ignacio Alfaro Maria Carme Masamunt Nuria Planell Alicia López-García Jesús Castro Marta Gallego Rebeca Barastegui Angel Giner Alejandro Vara Azucena Salas Elena Ricart Julián Panés Ingrid Ordás | 2019 | World Journal of Gastroenterology2019，25，14： | 0 |
| 15 | Sarcopenia in chronic viral hepatitis:From concept to clinical relevance显示文摘Although the frequency of metabolic risk factors for cirrhosis and hepatocellular carcinoma(HCC)is increasing,chronic hepatitis B(CHB)and chronic hepatitis C(CHC)remain the most relevant risk factors for advanced liver disease worldwide.In addition to liver damage,hepatitis B virus(HBV)and hepatitis C virus(HCV)infections are associated with a myriad of extrahepatic manifestations including mixed cryoglobulinaemia,lymphoproliferative disorders,renal disease,insulin resistance,type 2 diabetes,sicca syndrome,rheumatoid arthritislike polyarthritis,and autoantibody production.Recently,the list has grown to include sarcopenia.Loss of muscle mass or muscle function is a critical feature of malnutrition in cirrhotic patients and has been found in approximately 23.0%-60.0%of patients with advanced liver disease.Nonetheless,among published studies,there is significant heterogeneity in the aetiologies of hepatic diseases and measurement methods used to determine sarcopenia.In particular,the interaction between sarcopenia,CHB and CHC has not been completely clarified in a real-world setting.Sarcopenia can result from a complex and multifaceted virus-host-environment interplay in individuals chronically infected with HBV or HCV.Thus,in the present review,we provide an overview of the concept,prevalence,clinical relevance,and potential mechanisms of sarcopenia in patients with chronic viral hepatitis,with an emphasis on clinical outcomes,which have been associated with skeletal muscle loss in these patients.A comprehensive overview of sarcopenia in individuals chronically infected with HBV or HCV,independent of the stage of the liver disease,will reinforce the necessity of an integrated medical/nutritional/physical education approach in the daily clinical care of patients with CHB and CHC. | Marta Paula Pereira Coelho Pedro Alves Soares Vaz de Castro Thaís Pontello de Vries Enrico Antônio Colosimo Juliana Maria Trindade Bezerra Gifone Aguiar Rocha Luciana Diniz Silva | 2023 | World Journal of Hepatology2023，15，5： | 0 |
| 16 | Metabolic-associated fatty liver disease is associated with low muscle mass and strength in patients with chronic hepatitis B显示文摘BACKGROUND Although the prognostic relevance of sarcopenia has been increasingly recognised in the context of liver disease,there is a paucity of data evaluating body composition in patients with chronic hepatitis B(CHB).Beyond virus-related factors,nutritional and metabolic aspects can be associated with skeletal muscle abnormalities in these patients and should not be disregarded.AIM To evaluate the association between components of sarcopenia and demographic,clinical,lifestyle,nutritional,and biochemical variables in CHB patients.METHODS Dual-energy X-ray absorptiometry(DXA)was used to assess muscle mass by quantifying appendicular lean mass(ALM)adjusted for body mass index(ALMBMI).Muscle function was evaluated by hand grip strength(HGS)and the timed up and go test.Metabolic-associated fatty liver disease(MAFLD)was defined according to the criteria proposed by an international expert panel.A body shape index and the International Physical Activity Questionnaire were used to assess central obesity and physical activity level,respectively.RESULTS This cross-sectional study included 105 CHB outpatients followed at the tertiary care ambulatory centre(mean age,48.5±12.0 years;58.1%males;76.2%without cirrhosis;23.8%with compensated cirrhosis).The DXA-derived fat mass percentage was inversely correlated with the ALMBMI(r=-0.87)and HGS(r=-0.63).In the multivariable analysis,MAFLD,sedentarism and central obesity were positively and independently associated with low ALMBMI.MAFLD and central obesity were independently associated with low HGS.CONCLUSION MAFLD and central obesity were associated with low muscle mass and strength in patients with chronic hepatitis B,independent of the liver disease stage. | Cecy Maria de Lima Santos Matheus Duarte Brito Pedro Alves Soares Vaz de Castro Thais Pontello de Vries Nataly Lopes Viana Marta Paula Pereira Coelho Olívio Brito Malheiro Tatiana Bering Maria Cristina Gonzalez Rosangela Teixeira Rodrigo Dias Cambraia Gifone Aguiar Rocha Luciana Diniz Silva | 2022 | World Journal of Hepatology2022，14，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员